KANTERS USA HOLDING INC. – Trademark Portfolio
Entity Type: 03
KANTERS USA HOLDING INC. holds 9 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 6 filings in this category. The portfolio also extends into Class 3 (Cosmetics & Cleaning) across 3 Nice Classification classes. Currently, 6 trademarks are registered and 2 are pending. Notable registered marks include AGSANSOL, MINEXSOL, VITADERMA, CLEAROXSAN, and NUTRIHEALTH. The owner is based in LIESHOUT.
DE STATER 32
LIESHOUT 5737RV , NL
Showing of trademarks Trademarks
Trademark Classifications
KANTERS USA HOLDING INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Bleaching preparations and other substances for laundry use; cleaning, polishing, scouring
Frequently Asked Questions
How many trademarks does KANTERS USA HOLDING INC. have?
KANTERS USA HOLDING INC. has 9 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 pending, 1 cancelled.
What trademark classes does KANTERS USA HOLDING INC. file in?
KANTERS USA HOLDING INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 3 (Cosmetics & Cleaning), Class 1 (Chemicals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are KANTERS USA HOLDING INC.'s most well-known trademarks?
KANTERS USA HOLDING INC.'s registered trademark portfolio includes well-known marks such as AGSANSOL, MINEXSOL, VITADERMA, CLEAROXSAN, and NUTRIHEALTH. These are among 6 currently registered trademarks in the portfolio.
What is KANTERS USA HOLDING INC.'s trademark registration success rate?
KANTERS USA HOLDING INC. has a 86% trademark registration rate, with 6 out of 7 resolved applications resulting in successful registration. Currently, 2 applications are pending review.